Chao‐Hua Chiu

11.4k total citations
96 papers, 2.2k citations indexed

About

Chao‐Hua Chiu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Chao‐Hua Chiu has authored 96 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Pulmonary and Respiratory Medicine, 77 papers in Oncology and 21 papers in Cancer Research. Recurrent topics in Chao‐Hua Chiu's work include Lung Cancer Treatments and Mutations (79 papers), Lung Cancer Research Studies (40 papers) and Colorectal Cancer Treatments and Studies (25 papers). Chao‐Hua Chiu is often cited by papers focused on Lung Cancer Treatments and Mutations (79 papers), Lung Cancer Research Studies (40 papers) and Colorectal Cancer Treatments and Studies (25 papers). Chao‐Hua Chiu collaborates with scholars based in Taiwan, United States and South Korea. Chao‐Hua Chiu's co-authors include Chun‐Ming Tsai, Yuh‐Min Chen, Reury-Perng Perng, Kuo-Ting Chang, Tu‐Lai Yew, Shih‐Chieh Hung, Jir‐You Wang, Chih–Chien Tsai, Teh‐Ying Chou and Chun-Ming Tsai and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Chao‐Hua Chiu

92 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chao‐Hua Chiu Taiwan	25	1.5k	1.3k	486	418	278	96	2.2k
S. Cedrés Spain	20	1.2k 0.8×	1.3k 1.0×	363 0.7×	272 0.7×	81 0.3×	80	2.2k
Robert C. Hermann United States	15	868 0.6×	1.0k 0.8×	397 0.8×	178 0.4×	284 1.0×	38	1.8k
Nicolas Guibert France	25	1.2k 0.8×	866 0.6×	476 1.0×	957 2.3×	109 0.4×	87	1.9k
Leila Khoja United Kingdom	20	612 0.4×	1.7k 1.3×	416 0.9×	388 0.9×	124 0.4×	50	2.1k
Susanna Cappia Italy	24	748 0.5×	766 0.6×	651 1.3×	363 0.9×	125 0.4×	56	2.0k
Jong‐Mu Sun South Korea	25	1.1k 0.8×	1.3k 1.0×	528 1.1×	431 1.0×	46 0.2×	82	2.1k
Ryan D. Gentzler United States	20	1.4k 0.9×	2.1k 1.5×	285 0.6×	219 0.5×	105 0.4×	86	2.5k
Ashish M. Ingle United States	24	673 0.4×	788 0.6×	1.2k 2.5×	348 0.8×	383 1.4×	36	2.5k
Akito Hata Japan	25	1.4k 0.9×	1.1k 0.8×	320 0.7×	325 0.8×	54 0.2×	117	1.7k
Damien Pouessel France	20	790 0.5×	844 0.6×	377 0.8×	239 0.6×	63 0.2×	120	1.8k

Countries citing papers authored by Chao‐Hua Chiu

Since Specialization

Citations

This map shows the geographic impact of Chao‐Hua Chiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chao‐Hua Chiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chao‐Hua Chiu more than expected).

Fields of papers citing papers by Chao‐Hua Chiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chao‐Hua Chiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chao‐Hua Chiu. The network helps show where Chao‐Hua Chiu may publish in the future.

Co-authorship network of co-authors of Chao‐Hua Chiu

This figure shows the co-authorship network connecting the top 25 collaborators of Chao‐Hua Chiu. A scholar is included among the top collaborators of Chao‐Hua Chiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chao‐Hua Chiu. Chao‐Hua Chiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hung, Yi‐Ping, Pei‐Chang Lee, Yen‐Hwa Chang, et al.. (2024). Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas. Alimentary Pharmacology & Therapeutics. 61(3). 501–512. 3 indexed citations

Kim, Dong‐Wan, Byoung Chul Cho, Sang‐We Kim, et al.. (2024). Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study. Lung Cancer. 190. 107530–107530. 5 indexed citations

Fan, Yun, Alexander Drilon, Chao‐Hua Chiu, et al.. (2023). Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 25(2). e81–e86.e4. 1 indexed citations

Wu, Yuan‐Hung, Heng‐Sheng Chao, Chi‐Lu Chiang, et al.. (2023). Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell‐derived organoids. Thoracic Cancer. 14(25). 2591–2600. 4 indexed citations

Soo, Ross A., Jean‐François Martini, Anthonie J. van der Wekken, et al.. (2023). Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC. Journal of Thoracic Oncology. 18(11). 1568–1580. 22 indexed citations

Yang, James Chih‐Hsin, Wu‐Chou Su, Chao‐Hua Chiu, et al.. (2023). Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study. Investigational New Drugs. 41(2). 306–316. 8 indexed citations

Che, Ting-Fang, Chao‐Hua Chiu, Yu‐Chung Wu, et al.. (2023). Proliferative ability of circulating tumor cells is a prognostic factor in Early-Stage lung adenocarcinoma. Lung Cancer. 178. 198–205. 4 indexed citations

Ho, Hsiang‐Ling, Yuqiu Jiang, Chi‐Lu Chiang, et al.. (2022). Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. PLoS ONE. 17(4). e0267362–e0267362. 8 indexed citations

Yang, James Chih‐Hsin, Yuichiro Ohe, Chao‐Hua Chiu, et al.. (2022). Osimertinib plus Selumetinib in EGFR -Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical Cancer Research. 28(19). 4222–4231. 10 indexed citations

10.

Ho, Hsiang‐Ling, Fangyu Wang, Chi‐Lu Chiang, et al.. (2022). Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. International Journal of Molecular Sciences. 23(19). 11353–11353. 9 indexed citations

11.

Dziadziuszko, Rafał, Matthew Krebs, Filippo de Braud, et al.. (2021). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticROS1Fusion–Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 39(11). 1253–1263. 111 indexed citations

12.

Lin, Yen‐Ting, Chi‐Lu Chiang, Jen‐Yu Hung, et al.. (2021). Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non–small-cell lung cancer: a multicenter study using targeted next-generation sequencing. European Journal of Cancer. 156. 1–11. 25 indexed citations

13.

Huang, Chien‐Sheng, Hui‐Shan Chen, Po‐Kuei Hsu, et al.. (2021). Sequence for Surgical Resection of Primary Lung Tumor for Oligometastatic Non-small Cell Lung Cancer. The Annals of Thoracic Surgery. 113(4). 1333–1340. 3 indexed citations

14.

Chiang, Chi‐Lu, et al.. (2019). Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy. Lung Cancer. 138. 52–57. 4 indexed citations

15.

Chiang, Chi‐Lu, Yi‐Chen Yeh, & Chao‐Hua Chiu. (2019). EP1.14-35 Squamous Cell Carcinoma Transformation After Acquired Resistance to Osimertinib. Journal of Thoracic Oncology. 14(10). S1045–S1045.

16.

Lin, Hsi-Hsien, Chao‐Hua Chiu, Po‐Hsin Chou, et al.. (2019). Functional outcomes and survival after surgical stabilization for inoperable non-small-cell lung cancer with spinal metastasis of the thoracic and lumbar spines: a retrospective comparison between epidermal growth factor receptor-tyrosine kinase inhibitor and platinum-based chemotherapy groups. Spinal Cord. 58(2). 194–202. 8 indexed citations

17.

Chiang, Chi‐Lu, Chun‐Ming Tsai, Teh‐Ying Chou, et al.. (2012). Erlotinib in patients with advanced lung squamous cell carcinoma. Cancer Chemotherapy and Pharmacology. 71(1). 203–208. 7 indexed citations

18.

Chiu, Chao‐Hua, Yi‐Chen Yeh, Ko-Han Lin, et al.. (2011). Histological Subtypes of Lung Adenocarcinoma Have Differential 18F-Fluorodeoxyglucose Uptakes on the Positron Emission Tomography/Computed Tomography Scan. Journal of Thoracic Oncology. 6(10). 1697–1703. 41 indexed citations

19.

Chang, Gee‐Chen, Chun‐Ming Tsai, Kun‐Chieh Chen, et al.. (2006). Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 1(6). 520–525. 32 indexed citations

20.

Lai, Chun‐Liang, Chun‐Ming Tsai, Chao‐Hua Chiu, et al.. (2005). Phase II Randomized Trial of Tri-weekly Versus Days 1 and 8 Weekly Docetaxel as a Second-line Treatment of Advanced Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology. 35(12). 700–706. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact